CASI Pharmaceuticals, Inc. SEC filings CASIF
CASI Pharmaceuticals, Inc. has 157 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 2, 2026 |
| 6-K | Current report (foreign issuer) | Aug 14, 2026 | Aug 14, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Aug 13, 2026 |
| 6-K | Current report (foreign issuer) | Jul 15, 2026 | Jul 15, 2026 |
| 6-K | Current report (foreign issuer) | Jun 29, 2026 | Jun 29, 2026 |
| 25-NSE | Delisting notice | Jun 23, 2026 | — |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 2, 2026 |
| 20-F | Annual report (foreign issuer) | May 15, 2026 | Dec 31, 2025 |
| D | Filing | Apr 28, 2026 | — |
| NT 20-F | Filing | Apr 21, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Apr 20, 2026 | Apr 20, 2026 |
| 6-K | Current report (foreign issuer) | Apr 20, 2026 | Apr 20, 2026 |
| 6-K | Current report (foreign issuer) | Apr 15, 2026 | Apr 15, 2026 |
| 6-K | Current report (foreign issuer) | Mar 3, 2026 | Mar 3, 2026 |
| D | Filing | Feb 26, 2026 | — |
| 6-K | Current report (foreign issuer) | Feb 25, 2026 | Feb 25, 2026 |
| 6-K | Current report (foreign issuer) | Feb 20, 2026 | Feb 20, 2026 |
| 6-K | Current report (foreign issuer) | Feb 19, 2026 | Feb 19, 2026 |
| 6-K | Current report (foreign issuer) | Feb 10, 2026 | Feb 10, 2026 |
| D | Filing | Jan 28, 2026 | — |
| D | Filing | Jan 28, 2026 | — |
| 6-K | Current report (foreign issuer) | Jan 22, 2026 | Jan 22, 2026 |
| 6-K | Current report (foreign issuer) | Jan 13, 2026 | Jan 13, 2026 |
| 6-K | Current report (foreign issuer) | Dec 31, 2025 | Dec 30, 2025 |
| 6-K | Current report (foreign issuer) | Dec 23, 2025 | Dec 23, 2025 |
| 6-K | Current report (foreign issuer) | Dec 11, 2025 | Dec 11, 2025 |
| 6-K | Current report (foreign issuer) | Nov 19, 2025 | Nov 19, 2025 |
| 6-K | Current report (foreign issuer) | Nov 14, 2025 | Nov 14, 2025 |
| 6-K | Current report (foreign issuer) | Nov 10, 2025 | Nov 10, 2025 |
| 6-K | Current report (foreign issuer) | Sep 26, 2025 | Sep 26, 2025 |
| 6-K | Current report (foreign issuer) | Sep 2, 2025 | Sep 2, 2025 |
| 6-K | Current report (foreign issuer) | Aug 29, 2025 | Aug 29, 2025 |
| 6-K | Current report (foreign issuer) | Aug 27, 2025 | Aug 27, 2025 |
| 6-K | Current report (foreign issuer) | Aug 4, 2025 | Aug 4, 2025 |
| 6-K | Current report (foreign issuer) | Jul 22, 2025 | Jul 21, 2025 |
| 6-K | Current report (foreign issuer) | May 20, 2025 | May 20, 2025 |
| 6-K/A | Form 6-k/a | May 20, 2025 | May 20, 2025 |
| 6-K | Current report (foreign issuer) | May 16, 2025 | May 16, 2025 |
| 6-K | Current report (foreign issuer) | May 14, 2025 | May 14, 2025 |
| 6-K | Current report (foreign issuer) | May 12, 2025 | May 12, 2025 |
| 6-K | Current report (foreign issuer) | May 7, 2025 | May 7, 2025 |
| 6-K | Current report (foreign issuer) | Apr 9, 2025 | Apr 9, 2025 |
| 6-K | Current report (foreign issuer) | Apr 3, 2025 | Apr 3, 2025 |
| 6-K | Current report (foreign issuer) | Apr 3, 2025 | Apr 3, 2025 |
| 424B5 | Prospectus supplement | Apr 1, 2025 | — |
| 20-F | Annual report (foreign issuer) | Mar 31, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Mar 31, 2025 | Mar 31, 2025 |
| 6-K | Current report (foreign issuer) | Feb 10, 2025 | Feb 10, 2025 |
| 6-K | Current report (foreign issuer) | Jan 21, 2025 | Jan 21, 2025 |
| EFFECT | Filing | Dec 31, 2024 | — |
| CORRESP | Letter to the SEC | Dec 30, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2024 | — |
| 6-K | Current report (foreign issuer) | Dec 26, 2024 | Dec 26, 2024 |
| F-3/A | Form f-3/a | Dec 23, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 20, 2024 | — |
| 6-K | Current report (foreign issuer) | Dec 16, 2024 | Dec 16, 2024 |
| 6-K | Current report (foreign issuer) | Nov 15, 2024 | Nov 15, 2024 |
| 6-K | Current report (foreign issuer) | Sep 12, 2024 | Sep 12, 2024 |
| EFFECT | Filing | Sep 3, 2024 | — |
| CORRESP | Letter to the SEC | Aug 29, 2024 | — |
| F-3/A | Filing | Aug 29, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 23, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 16, 2024 | — |
| 6-K | Current report (foreign issuer) | Aug 16, 2024 | Aug 16, 2024 |
| S-8 | Employee stock plan registration | Aug 14, 2024 | — |
| 6-K | Current report (foreign issuer) | Jul 19, 2024 | Jul 19, 2024 |
| D | Filing | Jul 15, 2024 | — |
| 6-K | Current report (foreign issuer) | Jul 8, 2024 | Jul 8, 2024 |
| 6-K | Current report (foreign issuer) | Jun 27, 2024 | Jun 27, 2024 |
| 6-K | Current report (foreign issuer) | Jun 27, 2024 | Jun 27, 2024 |
| UPLOAD | Letter from the SEC | Jun 10, 2024 | — |
| CORRESP | Letter to the SEC | May 30, 2024 | — |
| UPLOAD | Letter from the SEC | May 22, 2024 | — |
| 6-K | Current report (foreign issuer) | May 15, 2024 | May 14, 2024 |
| EFFECT | Filing | May 10, 2024 | — |
| CORRESP | Letter to the SEC | May 9, 2024 | — |
| UPLOAD | Letter from the SEC | May 8, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | May 3, 2024 | — |
| 6-K | Current report (foreign issuer) | Apr 8, 2024 | Apr 8, 2024 |
| 6-K | Current report (foreign issuer) | Mar 28, 2024 | Mar 28, 2024 |
| 20-F | Annual report (foreign issuer) | Mar 28, 2024 | Dec 31, 2023 |
| 6-K | Current report (foreign issuer) | Mar 13, 2024 | Mar 13, 2024 |
| 6-K | Current report (foreign issuer) | Feb 29, 2024 | Feb 29, 2024 |
| 6-K | Current report (foreign issuer) | Feb 12, 2024 | Feb 9, 2024 |
| 6-K | Current report (foreign issuer) | Jan 30, 2024 | Jan 29, 2024 |
| 6-K | Current report (foreign issuer) | Dec 15, 2023 | Dec 15, 2023 |
| 6-K | Current report (foreign issuer) | Dec 8, 2023 | Dec 6, 2023 |
| 6-K | Current report (foreign issuer) | Nov 14, 2023 | Nov 14, 2023 |
| 6-K | Current report (foreign issuer) | Nov 8, 2023 | Nov 8, 2023 |
| UPLOAD | Letter from the SEC | Sep 19, 2023 | — |
| CORRESP | Letter to the SEC | Aug 25, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2023 | — |
| 6-K | Current report (foreign issuer) | Aug 11, 2023 | Aug 11, 2023 |
| 6-K | Current report (foreign issuer) | Aug 1, 2023 | Aug 1, 2023 |
| 6-K | Current report (foreign issuer) | Jul 20, 2023 | Jul 20, 2023 |
| S-8 POS | Form s-8 | May 23, 2023 | — |
| S-8 POS | Form s-8 | May 23, 2023 | — |
| S-8 POS | Form s-8 | May 23, 2023 | — |
| S-8 POS | Form s-8 | May 23, 2023 | — |
| 6-K | Current report (foreign issuer) | May 17, 2023 | May 17, 2023 |
| 6-K | Current report (foreign issuer) | May 17, 2023 | May 17, 2023 |
| 6-K | Current report (foreign issuer) | Apr 26, 2023 | Apr 26, 2023 |
| 20-F | Annual report (foreign issuer) | Apr 26, 2023 | Dec 31, 2022 |
| 6-K | Current report (foreign issuer) | Apr 26, 2023 | Apr 26, 2023 |
| 8-A12B | Form 8-a12b | Mar 27, 2023 | — |
| S-8 POS | Filing | Mar 21, 2023 | — |
| S-8 POS | Filing | Mar 21, 2023 | — |
| S-8 POS | Filing | Mar 21, 2023 | — |
| S-8 POS | Filing | Mar 21, 2023 | — |
| 6-K | Current report (foreign issuer) | Mar 21, 2023 | Mar 21, 2023 |
| 424B3 | Prospectus | Feb 14, 2023 | — |
| EFFECT | Filing | Feb 13, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| F-4/A | Filing | Feb 9, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2023 | — |
| F-4 | Filing | Jan 31, 2023 | — |
Showing 116 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CASIF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Beijing, China
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1962738
- Former names
- CASI Pharmaceuticals Holdings, Inc. (until Feb 14, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.